Corporate
Vanda Pharma's NEREUS Becomes First New Motion Sickness Drug in 40 Years — Shares Surge 18%
Dec 31, 2025
You're signed outSign in or to get full access.
VP
Vanda Pharmaceuticals (VNDA)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering Vanda Pharmaceuticals.